1. A major market potential by teaming up with leading MedTech companies as license partners
Bactiguard operates through license partnerships with leading global MedTech companies that apply the unique technology to their medical devices and sell them under their own brand or co-branded with Bactiguard. By teaming up, we will protect more patients and fuel mission, impact, and profitability for both Bactiguard and our license partners. Our coating technology is adaptable to any application area where it is important to reduce the risk of infections. According to a study conducted on Bactiguard’s behalf by McKinsey in 2022, the market for non-coated medical devices is estimated to be around USD 400 billion, and for our strategic therapeutic areas, it is estimated to be around USD 80 billion.
2. Making the world healthier by preventing infections
The challenges with healthcare-associated infections and antimicrobial resistance are on top of the global healthcare and sustainability agenda. Finding ways to prevent infections, and consequently decrease the use of antibiotics, is a priority. Costs related to healthcare associated infections, of which many are related to medical devices, are rocketing and antimicrobial resistance yearly causes the death of millions of people around the world, according to data from the World Health Organization (WHO). WHO has also defined antimicrobial resistance as one of the most serious threats to global health and modern medicine. Bactiguard’s infection prevention coating technology forms an important link in the healthcare value chain in the battle against antimicrobial resistance. Clinical studies have shown that the risk of catheter-associated urinary tract infections is reduced by 69 percent, of ventilator-associated pneumonia by 53 percent and of catheter-related blood infections by 52 percent when using medical devices with Bactiguard’s coating technology.
3. A safe, biocompatible, and effective coating technology
Bactiguard’s coating technology prevents bacteria from adhering to the surface of a medical device. When fewer bacteria adhere, the risk of biofilm formation and subsequent infection is significantly reduced. In a simplified manner, you can say that our technology repels bacteria rather than eliminates. More than 230 million Bactiguard coated catheters have been sold so far, and more than 40 clinical studies involving more than 100,000 patients have been performed. It is clinically proven that the technology is safe and biocompatible, and significantly reduces the risk of medical device related infections. We are continuously innovating the coating technology to make it applicable to a wide range of products. The coating is versatile and can be applied to almost all types of materials used in medical devices and implants, regardless of their surface characteristics. The process of coating medical devices is customizable and easy to scale up.